[Probable association between preeclampsia/eclampsia and paternal age: a pilot study]. / Posible asociación entre preeclampsia-eclampsia y la edad paterna: estudio piloto.

BACKGROUND: The preeclampsia is a multisystemic syndrome that occupied the first cause of maternal and fetal mortality around the world. Epidemiologic studies shown both mother and father contribute at the same risk for preeclampsia. OBJECTIVE: To determinate if there is an association between preeclampsia and paternal age. MATERIAL AND METHOD: Preeclampsia-eclampsia patients and couples were analyzed in agree to "National High Blood Pressure Education Program Working Group" classification, and a control group constituted by normal pregnant women and couples was included. RESULTS: There were 27 cases with mild preeclampsia and her couples, 13 cases with severe preeclampsia and her couples and 40 controls conformed by normal pregnant women and her couples. The statistical analysis of variance of the ages shown that men from preeclamptic group had a greater variance in contrast with man of control group (p < 0.001; valor of F = 5.084). CONCLUSIONS: Although is not clear how paternal age interview in preeclampsia risk, the interaction between paternal-maternal imprinting and spermatic senescence, followed by shortened telomeres of chromosome, could be produce the inactivity of a whole network of signals implicated in disease aetiology.

[Effectiveness of nasal vs oral estrogens in the climacteric syndrome]. / Eficacia de los estrógenos por vía nasal y oral en el síndrome climatérico.

BACKGROUND: Hormone replacement therapy reestablishes the diminished hormonal level and reduces mild, moderate and severe effects of climacteric. Its treatment includes estrogens, progestagens and a mixture of both. OBJECTIVE: To evaluate the efficacy of intranasal and oral estrogens in the climacteric syndrome. MATERIAL AND METHODS: 60 patients were evaluated with climacteric syndrome; 30 received intranasal estrogens (group A) and 30 received oral estrogens (group B). Age range, 34-64 years. The symptoms were classified as vasomotor, collagen related symptoms and tropic changes. The patients were evaluated four times a week, and the symptoms were measured as mild, moderate and severe according with the Guía de evaluación de riesgo en la paciente climatérica. RESULTS: Group A (intranasal estrogens) showed faster clinical response in the first two weeks (63%), compared with group B (30%). No side effects were found in both groups. CONCLUSIONS: Climacteric syndrome can be treated better and faster with intranasal estrogens than with oral estrogens, and without side effects.